Immunocore Holdings plc, a biotechnology company specializing in immunotherapies for cancer and other diseases, announced it will participate in the UBS Global Biopharma Conference and Jefferies London Global Healthcare Conference in November 2026. Management will present updates on their pipeline and recent progress, including their approved oncology drug KIMMTRAK for metastatic uveal melanoma. The presentations will be webcast live and available for replay on Immunocore's website, providing investors with insights into the company's developments and future plans.
Immunocore's upcoming investor presentations provide context for health sector activity on Pluang. Of 150 priced US health stocks, 108 advanced and 26 declined as of Nov 09, 2026 18:41 WIB. Notable movers include HIMS at USD 25.29 with a -2.73% change, MRVI at USD 7.35 down 2.26%, and INMD at USD 13.62 up 2.18%.
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
Credit Agricole Toulouse 31 disclosed its weekly transactions involving the buyback of its cooperative investment certificates (CCI) from November 2 to November 6, 2026. The bank repurchased varying volumes daily, with prices ranging around 98.82 to ...
Heineken N.V. has repurchased a total of 9,814,488 shares under the second tranche of its €1.5 billion share buyback program, spending approximately €704 million up to November 6, 2026. This tranche is part of a larger plan announced in February 2026...
Claritev Corporation reported Q3 2026 revenues of $268.3 million, up 9.1% from the previous year, with adjusted EBITDA increasing 4.4% to $162 million. Despite a net loss of $61.8 million, the company highlighted strong growth across its solutions an...
